×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
VCYT – veracyte, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
VCYT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/17
02:40 am
vcyt
Veracyte Names Kevin Haas as Chief Development and Technology Officer [Yahoo! Finance]
Low
Report
Veracyte Names Kevin Haas as Chief Development and Technology Officer [Yahoo! Finance]
3/16
04:15 pm
vcyt
Veracyte Names Kevin Haas as Chief Development and Technology Officer
Low
Report
Veracyte Names Kevin Haas as Chief Development and Technology Officer
3/14
06:59 am
vcyt
Veracyte (VCYT) was downgraded by Zacks Research from "strong-buy" to "hold".
Low
Report
Veracyte (VCYT) was downgraded by Zacks Research from "strong-buy" to "hold".
3/5
08:07 pm
vcyt
Veracyte (VCYT) had its "underweight" rating reaffirmed by Morgan Stanley.
Medium
Report
Veracyte (VCYT) had its "underweight" rating reaffirmed by Morgan Stanley.
3/3
07:39 am
vcyt
Veracyte (VCYT) Valuation Check After Strong 2025 Earnings And Reaffirmed 2026 Growth Outlook [Yahoo! Finance]
Low
Report
Veracyte (VCYT) Valuation Check After Strong 2025 Earnings And Reaffirmed 2026 Growth Outlook [Yahoo! Finance]
3/2
04:36 am
vcyt
Wisdom Bioscience Establishes Scientific Advisory Board to Advance Oral Cancer Diagnostics and Screening [Yahoo! Finance]
Low
Report
Wisdom Bioscience Establishes Scientific Advisory Board to Advance Oral Cancer Diagnostics and Screening [Yahoo! Finance]
2/26
08:03 am
vcyt
Veracyte (VCYT) had its price target raised by Needham & Company LLC from $44.00 to $48.00. They now have a "buy" rating on the stock.
Medium
Report
Veracyte (VCYT) had its price target raised by Needham & Company LLC from $44.00 to $48.00. They now have a "buy" rating on the stock.
2/26
04:44 am
vcyt
Veracyte Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Veracyte Q4 Earnings Call Highlights [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/16
04:17 pm
vcyt
Form 8-K VERACYTE, INC. For: Mar 13
Low
Report
Form 8-K VERACYTE, INC. For: Mar 13
3/10
05:10 pm
vcyt
Form 4 VERACYTE, INC. For: Mar 06 Filed by: Leite John
Low
Report
Form 4 VERACYTE, INC. For: Mar 06 Filed by: Leite John
3/10
05:10 pm
vcyt
Form 4 VERACYTE, INC. For: Mar 06 Filed by: Chambers Rebecca
Low
Report
Form 4 VERACYTE, INC. For: Mar 06 Filed by: Chambers Rebecca
3/10
05:10 pm
vcyt
Form 4 VERACYTE, INC. For: Mar 06 Filed by: Wygant Jonathan
Low
Report
Form 4 VERACYTE, INC. For: Mar 06 Filed by: Wygant Jonathan
3/10
05:10 pm
vcyt
Form 4 VERACYTE, INC. For: Mar 06 Filed by: Stapley Marc
Low
Report
Form 4 VERACYTE, INC. For: Mar 06 Filed by: Stapley Marc
3/10
05:10 pm
vcyt
Form 4 VERACYTE, INC. For: Mar 06 Filed by: McGuire Annie
Low
Report
Form 4 VERACYTE, INC. For: Mar 06 Filed by: McGuire Annie
3/10
05:10 pm
vcyt
Form 4 VERACYTE, INC. For: Mar 06 Filed by: Febbo Phillip G.
Low
Report
Form 4 VERACYTE, INC. For: Mar 06 Filed by: Febbo Phillip G.
3/6
04:33 pm
vcyt
Form 4 VERACYTE, INC. For: Mar 04 Filed by: Leite John
Low
Report
Form 4 VERACYTE, INC. For: Mar 04 Filed by: Leite John
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/23
Form 4 VERACYTE, INC. For: Mar 20 Filed by: Anderson Bonnie H
16.7%
3/25 Form SEC STAFF LETTER VERACYTE, INC. 15.6%
2/29 Veracyte Inc (NASDAQ: VCYT) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 8.3%
12/4 Veracyte Inc (NASDAQ: VCYT) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 7.9%
4/24 Form DEFA14A VERACYTE, INC. 7.9%
6/27 Veracyte to Release Second Quarter 2019 Financial Results on July 30, 2019 7.5%
8/12 Form 4 VERACYTE, INC. For: Aug 09 Filed by: JONES EVAN/ FA 6.7%
10/26 Veracyte Inc (NASDAQ: VCYT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $29.00 price target on the stock. 6.5%
4/7 Veracyte Names Tracy Morris as Vice President of Corporate Communications and Investor Relations 6.3%
10/19 Veracyte Inc (NASDAQ: VCYT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $29.00 price target on the stock. 6.1%
3/25 Form SEC STAFF LETTER VERACYTE, INC. 15.6%
2/29 Veracyte Inc (NASDAQ: VCYT) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 8.3%
12/4 Veracyte Inc (NASDAQ: VCYT) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 7.9%
4/24 Form DEFA14A VERACYTE, INC. 7.9%
6/27 Veracyte to Release Second Quarter 2019 Financial Results on July 30, 2019 7.5%
8/12 Form 4 VERACYTE, INC. For: Aug 09 Filed by: JONES EVAN/ FA 6.7%
10/26 Veracyte Inc (NASDAQ: VCYT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $29.00 price target on the stock. 6.5%
4/7 Veracyte Names Tracy Morris as Vice President of Corporate Communications and Investor Relations 6.3%
10/19 Veracyte Inc (NASDAQ: VCYT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $29.00 price target on the stock. 6.1%
TOP News Decliners
4/1
Veracyte Announces Novel Gene Fusion Detection with the Afirma Xpression Atlas, Which May Inform Targeted Treatment Decisions for Thyroid Cancer Patients
-16.6%
3/11 Form 4 VERACYTE, INC. For: Mar 10 Filed by: Anderson Bonnie H -16.1%
10/22 Veracyte Announces Third Quarter 2019 Financial Results and Business Progress -15.7%
8/13 Form 4 VERACYTE, INC. For: Aug 12 Filed by: Anderson Bonnie H -8.2%
2/21 Veracyte Inc (NASDAQ: VCYT) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -8.1%
10/24 Veracyte Inc (NASDAQ: VCYT) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -7.3%
9/3 Veracyte Announces Publication of New Study Characterizing Gene Alterations in Thyroid Cancer -7.1%
8/1 Veracyte Inc (NASDAQ: VCYT) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -6.8%
7/30 Form 10-Q VERACYTE, INC. For: Jun 30 -6.7%
4/14 Form 8-K VERACYTE, INC. For: Apr 13 -6.3%
3/11 Form 4 VERACYTE, INC. For: Mar 10 Filed by: Anderson Bonnie H -16.1%
10/22 Veracyte Announces Third Quarter 2019 Financial Results and Business Progress -15.7%
8/13 Form 4 VERACYTE, INC. For: Aug 12 Filed by: Anderson Bonnie H -8.2%
2/21 Veracyte Inc (NASDAQ: VCYT) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -8.1%
10/24 Veracyte Inc (NASDAQ: VCYT) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -7.3%
9/3 Veracyte Announces Publication of New Study Characterizing Gene Alterations in Thyroid Cancer -7.1%
8/1 Veracyte Inc (NASDAQ: VCYT) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -6.8%
7/30 Form 10-Q VERACYTE, INC. For: Jun 30 -6.7%
4/14 Form 8-K VERACYTE, INC. For: Apr 13 -6.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: